MD Anderson and Replay Announce FDA Clearance of IND Application for First-in-Class TCR NK Cell Therapy for Sarcoma
June 21, 2023
June 21, 2023
HOUSTON, Texas, June 21 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
First-in-human Phase I study of NY-ESO-1 TCR/IL-15 NK for advanced synovial sarcoma and myxoid/round cell liposarcoma anticipated to commence Q3 2023
* * *
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the I . . .
* * *
First-in-human Phase I study of NY-ESO-1 TCR/IL-15 NK for advanced synovial sarcoma and myxoid/round cell liposarcoma anticipated to commence Q3 2023
* * *
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the I . . .